title: [New drugs in type 2 diabetes mellitus therapy].
abstract: The objective in developing a new type 2 diabetes therapy is to achieve greater safety and better efficacy. Newly registered drugs include lixisenatide, QW exenatide, dapagliflozin and insulin degludec. Once weekly gliptins and other substances are under development.
authors.affiliation: Interni klinika 2. lekarske fakulty UK a FN Motol Praha. milan.kvapil@fnmotol.cz
authors.forename: M
authors.initials: M
authors.lastname: Kvapil
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D000077270:Exenatide; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*; D000067758:Glucagon-Like Peptide-2 Receptor
chemical_list: D001559:Benzhydryl Compounds; D054873:Dipeptidyl-Peptidase IV Inhibitors; D000077270:Exenatide; D005960:Glucosides; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D010455:Peptides; D014688:Venoms; C529054:dapagliflozin; C571886:insulin degludec; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor